| FDA approves new combination for hypertension - TheHeart.Org |
|
|
TheHeart.Org Patients with renal impairment should be monitored for worsening renal function. Hypokalemia is a dose-dependent adverse reaction that may develop with chlorthalidone; Edarbyclor attenuates chlorthalidone-associated hypokalemia. ... FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the |